Innate Pharma partners with Sobi to license lacutamab in T-cell lymphoma

Innate Pharma and Swedish Orphan Biovitrum (Sobi) announced on August 10, 2026 a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), described as a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL.¹

Under the deal, Innate will run the TELLOMAK-3 Phase 3 confirmatory trial in CTCL to support a planned filing for accelerated approval in Sézary syndrome.¹ Data from that study are also meant to back later filings for full approval in Sézary syndrome and in mycosis fungoides, which the companies describe as the most common CTCL subtype. Sobi is set to gain exclusive worldwide commercial rights if accelerated approval is granted, and could take over full global development rights if the Phase 3 results are positive. The deal's closing still depends on standard closing conditions, including antitrust clearance, the companies said.

On financial terms, Sobi will pay Innate $75 million at closing, with Innate eligible for up to $40 million tied to near-term Sézary syndrome development milestones and up to $465 million linked to Sobi's option to take full development rights plus future regulatory and commercial milestones, along with tiered double-digit royalties on net sales.¹

Lacutamab is described as a first-in-class anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma.¹ Regulators have granted the program Fast Track designation from the FDA, PRIME designation from the EMA for Sézary syndrome, Orphan Drug designation in the U.S. and EU for CTCL, and Breakthrough Therapy Designation from the FDA for relapsed or refractory Sézary syndrome.¹ The planned Phase 3 trial is described as an open-label, multicenter, randomized study enrolling patients with Sézary syndrome and mycosis fungoides who have failed at least one prior systemic therapy,¹ with progression-free survival as the primary endpoint across a confirmatory Sézary syndrome cohort and a registrational mycosis fungoides cohort.¹